Transplanted CAR stem cells persisted long term and showed multilineage engraftment in tissues that harbor HIV.

Researchers developed a new CAR T-cell therapy that targets specific growth factor receptors in glioblastoma to eliminate brain tumors.

Pairing CARs with a synthetic receptor makes T cells more lethal tumor killers.

A new mammalian display platform enhances antibody discovery for challenging protein targets.

Katie McKenna discusses a combination CAR T and viral therapy that kills solid tumors.

Katie McKenna will discuss how oncolytic viral therapy enhances CAR-T cell killing of cancer cells.

A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.

When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.

Download this eBook to take a closer look at past efforts, modern challenges, and future advances!

Join us to learn about adoptive cell therapies from leading experts in the field of cancer immunology. 

There’s a new cell-based cancer immunotherapy on the block.

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.

The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.

We may not have personal jetpacks yet, but the past decade has been marked by life-science revolutions, and the coming years have even more biological breakthroughs in store.

Scientists show the approach can kill cells that cause hardening of heart tissue in mice.

The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.

About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.

Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.